Axonics Modulation Technologies
Irvine
California
United States
154 articles about Axonics Modulation Technologies
-
Axonics® Expands Sacral Neuromodulation Intellectual Property Portfolio
8/17/2022
Axonics, Inc., a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, announced that in the last twelve months, the United States Patent and Trademark Office has granted eight patents and allowed four patent applications related to the company’s sacral neuromodulation technology.
-
Axonics® Announces Pricing of Public Offering of Common Stock - Aug 03, 2022
8/3/2022
Axonics, Inc., a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, announced that it priced its previously announced underwritten public offering of 1,750,000 shares of its common stock.
-
Axonics® Announces Proposed Public Offering of Common Stock - Aug 02, 2022
8/2/2022
Axonics, Inc., a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, announced that it has commenced a proposed underwritten public offering of 1,750,000 shares of its common stock.
-
Axonics® Files PMA Supplement with FDA for Fourth Generation Rechargeable Neurostimulator
5/31/2022
Axonics ® Files PMA Supplement with FDA for Fourth Generation Rechargeable Neurostimulator.
-
Axonics® Reports First Quarter 2022 Financial Results
5/5/2022
Axonics, Inc. today reported financial results for the three months ended March 31, 2022.
-
New Study Finds More Than 60% of Adult Women in the U.S. Experience Urinary Incontinence
1/25/2022
Axonics, Inc., a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, highlighted the publication of a new study that provides updated estimates of urinary incontinence prevalence in the U.S.
-
Axonics® Reports Preliminary Fourth Quarter and Fiscal Year 2021 Revenue
1/6/2022
Axonics, Inc., a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, reported preliminary unaudited net revenue for the three months and fiscal year ended December 31, 2021.
-
Axonics® to Report Second Quarter 2021 Financial Results on August 5, 2021
7/8/2021
Axonics, Inc., a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, will report second quarter 2021 financial results after the market closes on Thursday, August 5, 2021.
-
Axonics® Announces Proposed Public Offering of Common Stock - May 11, 2021
5/11/2021
Axonics, Inc., a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, announced that it has commenced a proposed public offering of $150,000,000 in shares of its common stock.
-
Axonics® to Report First Quarter 2021 Financial Results on May 6, 2021
4/15/2021
Axonics ® to Report First Quarter 2021 Financial Results on May 6, 2021
-
Axonics® to Participate in the Barclays Global Healthcare Conference
3/3/2021
Axonics Modulation Technologies, Inc., a global medical technology company that has developed and is commercializing novel products for the treatment of bladder and bowel dysfunction, is scheduled to participate in the virtual Barclays Global Healthcare Conference on March 10, 2021.
-
Axonics® Announces Strategic Alliance for the Manufacture of New Non-Rechargeable Implantable Sacral Neuromodulation Device
3/2/2021
Axonics Modulation Technologies, Inc., a global medical technology company that has developed and is commercializing novel products for the treatment of bladder and bowel dysfunction, announced it has entered into a strategic alliance with Micro Systems Technologies, a leading manufacturer of medical microelectronics.
-
Axonics® Reports Fourth Quarter and Fiscal Year 2020 Results
2/25/2021
Axonics Modulation Technologies, Inc., a medical technology company that has developed and is commercializing novel implantable sacral neuromodulation devices for the treatment of urinary and bowel dysfunction, reported results for the fourth quarter and fiscal year ended December 31, 2020.
-
Axonics® Expands into Stress Urinary Incontinence with the Acquisition of Bulkamid®
2/25/2021
Axonics Modulation Technologies, Inc. (Nasdaq: AXNX), a medical technology company that has developed and is commercializing novel implantable sacral neuromodulation (SNM) devices for the treatment of urinary and bowel dysfunction, today announced that it has acquired privately-held Contura Ltd. and its flagship product, Bulkamid, a best-in-class urethral bulking agent for women with stress urinary incontinence (SUI
-
Axonics® to Report Fourth Quarter and Fiscal Year 2020 Financial Results on February 25, 2021
2/22/2021
Axonics Modulation Technologies, Inc. (Nasdaq: AXNX), a medical technology company that has developed and is commercializing novel implantable sacral neuromodulation (SNM) devices for the treatment of urinary and bowel dysfunction, will report fourth quarter and fiscal year 2020 financial results after the market closes on Thursday, February 25, 2021.
-
Axonics® to Participate in the Society for Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction 2021 Winter Meeting
2/18/2021
Axonics Modulation Technologies, Inc. announced it is participating as a platinum sponsor of the Society for Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction 2021 Winter Meeting, which is being held virtually from February 25-27.
-
Axonics® Receives FDA Approval for Third-Generation Implantable Neurostimulator
2/16/2021
Axonics Modulation Technologies, Inc., a medical technology company that has developed and is commercializing novel implantable sacral neuromodulation devices for the treatment of urinary and bowel dysfunction, has received PMA supplement approval from the U.S. Food & Drug Administration for its third-generation implantable neurostimulator.
-
Axonics® to Participate in the SVB Leerink Global Healthcare Conference
2/11/2021
Axonics Modulation Technologies, Inc., a medical technology company that has developed and is commercializing novel implantable sacral neuromodulation devices for the treatment of urinary and bowel dysfunction, will participate in the virtual SVB Leerink Global Healthcare Conference on February 24, 2021.
-
Axonics® Reports Preliminary Fourth Quarter and Fiscal Year 2020 Revenue
1/25/2021
Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that has developed and is commercializing novel implantable sacral neuromodulation (SNM) devices for the treatment of urinary and bowel dysfunction, today reported preliminary unaudited net revenue for the three months and fiscal year ended December 31, 2020.
-
Axonics® to Participate in Piper Sandler Virtual Healthcare Conference
11/19/2020
Axonics Modulation Technologies, Inc., a medical technology company that has developed and is commercializing novel implantable sacral neuromodulation devices for the treatment of urinary and bowel dysfunction, is scheduled to participate in the Piper Sandler Virtual Healthcare Conference on December 1-2, 2020.